Top 3 results from TAILORx
TAILORx: Trial Assigning IndividuaLized Options for treatment = Tailor Rx
1. What is the proportion of the women with hormone-receptorâpositive, human epidermal growth factor receptor 2 (HER2)ânegative, armpit nodeânegative early breast cancer who don't need chemo after primary surgery?
The 10,273 participants were divided into 3 classes first by Recurrence Score (0-100), and this was a non-randomized process. Then, 6,907 participants whose scores were 11-25 were randomly assigned to a group without or with chemo.
It's known: Recurrence Score â¤10 not need chemo & âĽ26 need chemo. How about 11-25? This trial tries to answer this.
There were 9719 eligible patients with follow-up information who were included in the main analysis set. (1619 + 3399 + 3312 + 1389)
Figure 1. Registration, Randomization, and Follow-up.
CONCLUSIONS Chemo had no added efficacy in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, armpit nodeânegative breast cancer who had a mid-range 21-gene recurrence score (11-25), although some benefit of chemo was found in women 50 years of age or younger with a recurrence score of 16-25.
Figure S11. Recurrence Score 11 to 25: Subgroup Analysis for Comparison of Assigned Treatment Arms. DFS, invasive disease-free survival; RS = Recurrence Score; Pre, premeno, pre-menopause; post, post-menopause
[9719 - 1389 - (923 + 492)]/9719 Ă 100% â 71%
2. Most readers could associate 18-50 years old with menstruation, but is there an association between menstruation/menopause and young women scored 16-25 needing chemo? From the Fig above, we can't see such an association because [Pre, RS 21-25] shows no added  benefit of chemo. See more of Fig S11:
Fig S11. More. DRFI (distant recurrence-free interval), freedom from breast cancer recurrence at a distant site
Fig S11. More. RFI (recurrence-free interval), freedom from breast cancer recurrence at a distant or local-regional site
From Fig S11 More, an weak association between [Pre, RS 21-25] and chemo need appears, but which is weakened further by the weird results from first analysis. Still, the authors wrote about it:
A greater treatment effect from adjuvant chemotherapy has been noted in younger women,7 which may be at least partly explained by an antiestrogenic effect associated with premature menopause induced by chemotherapy.27
We did not collect data on chemotherapy-induced menopause. It remains unclear whether similar benefits could be achieved with ovarian suppression plus an aromatase inhibitor instead of chemotherapy. 28,29













